Docality.com Logo
 
Dr. Maher  Hanna  Dds image

Dr. Maher Hanna Dds

117 State Route 35
Eatontown NJ 07724
973 312-2358
Medical School: Other - Unknown
Accepts Medicare: No
Participates In eRX: No
Participates In PQRS: No
Participates In EHR: No
License #: 22DI02596100
NPI: 1649661612
Taxonomy Codes:
122300000X

Request Appointment Information

Awards & Recognitions

About Us

Practice Philosophy

Conditions

Medical Malpractice Cases

None Found

Medical Board Sanctions

None Found

Referrals

None Found

Publications

Merkel-cell carcinoma of the pinna. - The Journal of laryngology and otology
Merkel-Cell carcinoma is a rare malignant skin tumour. It was first described as 'Trabecular Carcinoma' by Toker in 1972. Since then many reports have appeared in the literature, mainly in the dermatology, pathology and to a lesser extent, in the plastic surgery journals. Surprisingly, the topic is rarely discussed in the otolaryngology literature, though nearly fifty per cent of these tumours arise in the head and neck.
Development of a core outcome set for clinical trials in facial aging: study protocol for a systematic review of the literature and identification of a core outcome set using a Delphi survey. - Trials
Facial aging is a concern for many patients. Wrinkles, loss of volume, and discoloration are common physical manifestations of aging skin. Genetic heritage, prior ultraviolet light exposure, and Fitzpatrick skin type may be associated with the rate and type of facial aging. Although many clinical trials assess the correlates of skin aging, there is heterogeneity in the outcomes assessed, which limits the quality of evaluation and comparison of treatment modalities. To address the inconsistency in outcomes, in this project we will develop a core set of outcomes that are to be evaluated in all clinical trials relevant to facial aging.A long list of measureable outcomes will be created from four sources: (1) systematic medical literature review, (2) patient interviews, (3) other published sources, and (4) stakeholder involvement. Two rounds of Delphi processes with homogeneous groups of physicians and patients will be performed to prioritize and condense the list. At a consensus meeting attended by physicians, patients, and stakeholders, outcomes will be further condensed on the basis of participant scores. By the end of the meeting, members will vote and decide on a final recommended set of core outcomes. Subsequent to this, specific measures will be selected or created to assess these outcomes.The aim of this study is to develop a core outcome set and relevant measures for clinical trials relevant to facial aging. We hope to improve the reliability and consistency of outcome reporting of skin aging, thereby enabling improved evaluation of treatment efficacy and patient satisfaction.Core Outcome Measures in Effectiveness Trials (COMET) Initiative, accessible at http://www.comet-initiative.org/studies/details/737 . Core Outcomes Set Initiative, (CSG-COUSIN) accessible at https://www.uniklinikum-dresden.de/de/das-klinikum/universitaetscentren/zegv/cousin/meet-the-teams/project-groups/core-outcome-set-for-the-appearance-of-facial-aging . Protocol version date is 28 July 2016.
Neuropathic Pain Medication Use Does Not Alter Outcomes of Spinal Cord Stimulation for Lower Extremity Pain. - Neuromodulation : journal of the International Neuromodulation Society
Spinal cord stimulation (SCS) for the treatment of lower extremity pain is believed to the result of increased activity in the descending inhibitory and decreased activity in the ascending excitatory tracts. Evidence suggests that the analgesia afforded by SCS may be altered using certain neuropathic pain medications that also modulate neurotransmitters in these sensory tracts. We hypothesize that neuropathic pain medications may alter the response to SCS therapy.One hundred and fifteen subjects undergoing SCS therapy for lower extremity pain were retrospectively examined. The pharmacologic profile, including stable use of neuropathic and opioid medications, were recorded. Three separate logistic regression models examined the odds ratio of primary outcomes; a successful SCS trial, a 50% decrease in pain or a 50% reduction in opioid use one year after implant.Neither the use of opioids or neuropathic pain medications were associated with changes in the odds of a successful SCS trial or a 50% pain reduction. A higher dose of chronic opioids use prior to a trial was associated with greater odds of having a 50% reduction in opioid use following implant. OR 1.02, 95% CI 1.01-1.02, p-value < 0.01).The use of neuropathic pain medications did not change the odds of either a successful SCS trial, or of experiencing a 50% reduction in pain at one year. The association between higher opioid doses and greater odds of a 50% reduction in opioid use may be the reflective of SCS's ability to reduce opioid reliance in chronic pain patients.© 2017 International Neuromodulation Society.

Map & Directions

117 State Route 35 Eatontown, NJ 07724
View Directions In Google Maps

Nearby Doctors

10 Churchhill Downs Dr
Tinton Falls, NJ 07724
732 891-1590
2 Industrial Way W
Eatontown, NJ 07724
732 424-4477
615 Hope Rd Ste 5
Eatontown, NJ 07724
732 711-1000
6 Industrial Way W St B Hypertension & Nephrology Assoc
Eatontown, NJ 07724
732 601-1200
1 Industrial Way W Suite C
Eatontown, NJ 07724
732 426-6451
776 Shrewsbury Ave Ste 201
Tinton Falls, NJ 07724
732 304-4949
615 Hope Rd Ste 5
Eatontown, NJ 07724
732 711-1000
37 Highway 35
Eatontown, NJ 07724
732 449-9101